The development of this immunological alternative has demanded a two-year research and an outlay of about US$ 6 million to Centrovet. The company expects to produce about 60 million doses only during 2009. Demand will outstrip supply.
Other contenders in the race were: Pharmaq, who announced a proof of concept of an ISA vaccine back in January 2008 and Corporation Farmaceutica which announced trials of a vaccine in October 2008.